uploads/2019/01/about-3887439_1280.jpg

Analysts’ Recommendations for Pfizer in January

By

Updated

Share price movements

Pfizer (PFE) is a large pharmaceutical company with a highly diversified business model. It offers a large portfolio of products across multiple geographic markets. Its current market cap is $243.01 billion.

On January 3, the company closed at $42.04, 2.80% lower than its previous day’s closing price. The stock’s 52-week high is $46.47, while its 52-week low is $33.20. Currently, the stock is trading at a discount of 9.53% to its 52-week high and a premium of 26.63% to its 52-week low.

Based on its closing price on January 3, the company had reported returns of -0.36% in the last week, -9.06% in the last month, and -4.93% in the last quarter. Pfizer had also reported returns of 15.65% in the last half year, 15.37% in the last year, and -3.69% year-to-date.

On December 31, 2018, Pfizer reported a rise of 24.08% compared to its share price on January 2, 2018, and emerged as one of the best performers in the Dow Jones Industrial Average (DJI).

Article continues below advertisement

Analysts’ recommendations and target prices

The 12-month consensus analyst recommendation for Pfizer as of January 3 is a “hold.” The stock’s 12-month consensus target price is $45.32, 7.80% higher than its closing price on January 3. The highest target price estimate for the company is $54, and the lowest target price estimate is $36.

Of the 16 analysts covering Pfizer on January 3, one rated the stock as a “strong buy,” five rated it as a “buy,” eight rated it as a “hold,” and one rated it as a “strong sell.”

In the next article, we’ll discuss analysts’ recommendations for Eli Lilly in greater detail.

Advertisement

More From Market Realist